

Corporate Factsheet

March 2026

Company Profile

OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. OrbusNeich is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 6929.

Employees worldwide


1,400+

Leadership


20+ Years of experience

Core management team

Innovation


220+

Granted patents & published patent applications globally

Bases


2 R&D facilities
3 Production centers

Capacity


2.1 million balloons and stents

Annual production capacity

Sales network


70+

Countries & regions

Excellent capabilities in R&D, Operation and Commercialization

R&D

R&D development

- Over 220 granted patents and published patent applications globally
- Clinical application of Sapphire PTX, a coronary paclitaxel DCB, is expected to be submitted to PMDA in Q1 2026
- JADE Score, a peripheral scoring balloon, is expected to be submitted to PMDA and the FDA for registration in 2026

Product approval

- PMDA: Teleport Glide, Scoreflex QUAD, EZGuide LL (Large Lumen), Vascaid, SIDEPASS
- CE: JADE PLUS, Teleport Glide
- NMPA: GuidingArk guiding catheter, Teleport XT

Operation

New facility construction

- Held topping-out ceremony of our largest R&D and manufacturing facility in Hangzhou in H2 2025; Construction of the main structure was completed, and renovations have been underway since late 2025.

Third-party collaboration

- Strengthened partnership with SonoScape by distributing IVUS products across key APAC and European markets

Commercialization

- Sales network covering over 70 countries and regions
- Direct and distributor sales accounted for 58% and 42% of total sales in 2025 respectively
- Established a direct sales team in the Netherlands in H2 2025 and is establishing another team in Belgium in 2026, with the goal of achieving direct sales to hospitals in these two markets within same year
- Held or participated in around 80 seminars, workshops, conferences, discussion panels and Physician Exchange Program globally in 2025


 Headquarters
 Hong Kong, China

 R&D and Production Center
 Shenzhen, China

 Production Center &
 EMEA Regional Headquarters
 Hoevelaken, the Netherlands

 Production Center
 Weil am Rhein, Germany

 Advanced Technology
 Laboratory
 Tokyo, Japan

Product portfolio





As of Dec 31, 2025

	Lesion Access	Lesion Preparation	Lesion Therapy	Lesion Optimization
PCI 	Teleport Microcatheter SAPPHIRE 3 Coronary Dilatation Catheter Teleport XT Microcatheter SAPPHIRE II PRO Coronary Dilatation Catheter Xtenza Guide Catheter Extension EZGuide Guide Catheter Extension GuidingArk Dual Lumen Catheter SIDEPASS Dual Lumen Catheter	SAPPHIRE 3 Coronary Dilatation Catheter SAPPHIRE II PRO Coronary Dilatation Catheter SAPPHIRE NC 24 Coronary Dilatation Catheter scoreflex NC Balloon Dilatation Catheter scoreflex TRIO Balloon Dilatation Catheter scoreflex QUAD Balloon Dilatation Catheter Vascuaid Aspiration Catheter	COMBO+ PLUS DUAL THERAPY STENT eucaLimus Coronary Stent System with Sirolimus Drug Coating SUPPORT C Paclitaxel Coated PTCA Catheter	NC SAPPHIRE 24 CUSTOMARY CLEARANCE CATHETER
PTA 	Teleport Microcatheter SAPPHIRE II PRO Coronary Dilatation Catheter Teleport XT Microcatheter Teleport Glide Microcatheter	JADE PTA BALLOON CATHETER JADE PLUS PTA BALLOON CATHETER JADE 2 PTA BALLOON CATHETER scoreflex PTA PTA BALLOON CATHETER	VITUS Paclitaxel Coated PTA Catheter	JADE PTA BALLOON CATHETER JADE 2 PTA BALLOON CATHETER JADE PLUS PTA BALLOON CATHETER

Key Financial Figures

Breakdown of revenue for 2025



Corporate Headquarters

Address | Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Shatin, N.T. Hong Kong

Phone | +852 2802 2288

Email | pr@orbusneich.com

www.OrbusNeich.com